Dasabuvir sodium; ombitasvir; paritaprevir; ritonavir - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir and what is the scope of patent protection?
Dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are twenty patents protecting this compound. Additional information is available in the individual branded drug profile pages.Dasabuvir sodium; ombitasvir; paritaprevir; ritonavir has six hundred and three patent family members in fifty-four countries.
Summary for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
International Patents: | 603 |
US Patents: | 20 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir |
DailyMed Link: | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
Generic Entry Dates for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, EXTENDED RELEASE;ORAL |
Generic Entry Dates for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
Expired US Patents for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Lithuania | PA2017033 | ⤷ Try a Trial | |
Brazil | 122012005261 | Inibidores de protease de serina para hepatite c macrocíclica no tratamento de infecção por hcv | ⤷ Try a Trial |
Slovenia | 2203431 | ⤷ Try a Trial | |
Chile | 2013002299 | Compuestos derivados de heterociclos, inhibidores de la replicacion del virus de la hepatitis c; composicion farmaceutica que los comprende; util en el tratamiento de una infeccion por vhc. (divisional solicitud 689-2011). | ⤷ Try a Trial |
Croatia | P20160408 | ⤷ Try a Trial | |
United Kingdom | 201418014 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2340029 | 304 50009-2015 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: EU/1/14/982/001 20150119 |
2368890 | 207 50010-2015 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982/001 20150119 |
2692346 | 17C1040 | France | ⤷ Try a Trial | PRODUCT NAME: PIBRENTASVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/17/1213 20170728 |
2203431 | 38/2015 | Austria | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR ODER EIN SALZ DAVON, EINSCHLIESSLICH DASABUVIR-NATRIUM-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/14/983 20150115 |
2368890 | C20150016 00154 | Estonia | ⤷ Try a Trial | PRODUCT NAME: OMBITASVIIR;REG NO/DATE: EU/1/14/982 19.01.2015 |
2203431 | C02203431/01 | Switzerland | ⤷ Try a Trial | BEI DER ANMELDUNG WURDE DER INHABER IRRTUEMLICH DOPPELT ERFASST. |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |